The government has taken a significant step toward improving drug quality and patient safety by formalising two institutional partnerships aimed at strengthening oversight and expanding pharmaceutical research capabilities. The initiative focuses on tighter quality checks for medicines distributed under the Jan Aushadhi scheme and advancing scientific standards in emerging therapies.
The Indian Pharmacopoeia Commission (IPC), under the Ministry of Health and Family Welfare, has signed a memorandum of understanding with the Pharmaceuticals & Medical Devices Bureau of India to enhance quality assurance for medicines sold through Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs).
Under this collaboration, PMBI may submit randomly selected drug batches from Jan Aushadhi outlets to IPC for independent testing. This introduces an additional verification layer, aimed at ensuring consistency and reliability in low-cost generic medicines.
The partnership will also promote the adoption of the National Formulary of India to encourage rational prescribing and dispensing practices across these centres.
A key focus area is strengthening pharmacovigilance under the Pharmacovigilance Programme of India. The initiative includes expanding adverse drug reaction (ADR) reporting systems and improving accessibility for patients and healthcare providers.
Jan Aushadhi centres will display PvPI QR codes and helpline details to facilitate real-time reporting of drug-related issues. Additionally, training programmes will be conducted for pharmacists and stakeholders to promote responsible drug use and improve patient safety outcomes.
In a parallel move, IPC has partnered with the National Institute of Pharmaceutical Education and Research, Hajipur to strengthen research and standard-setting in pharmaceutical sciences.
The collaboration will focus on advanced research areas such as impurity profiling, including genotoxic impurities like nitrosamines. It will also support the development of analytical methods, quality control protocols, and reference standards for biologics, biosimilars, and emerging treatments such as cell and gene therapies.
The agreement further includes academic exchange programmes, shared use of analytical infrastructure, and opportunities for internships and fellowships.
These dual partnerships signal a more structured and science-driven approach to drug regulation in India. By combining stricter quality checks with enhanced research capabilities, the government aims to improve trust in affordable medicines while preparing the ecosystem for next-generation therapies.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Published on: Apr 24, 2026, 3:55 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
